Isis Pharmaceuticals (ISIS)

Add to Watchlists
Create an Alert
35.20 +0.00  +0.00% NASDAQ Apr 24, 8:00PM BATS Real time Currency in USD
View Full Chart
ISIS Price Chart
View All Events

ISIS Events

Date Type Description
Feb 28 Misc Isis Pharmaceuticals Q4 2013 Earning Conference Call
Feb 28 Earnings Isis Pharmaceuticals Q4 2013 Earning Result. Estimate: -0.17.
Nov 05 Misc Webcast Alert: Isis Pharmaceuticals' Third Quarter 2013 Financial Results Conference Call
Nov 05 Earnings Webcast Alert: Isis Pharmaceuticals' Third Quarter 2013 Financial Results. Estimate: -0.26.
Sep 09 Misc Isis Pharmaceuticals Conference Call to Discuss Its New Strategic Collaboration With Biogen Idec
Aug 06 Misc Webcast Alert: Isis Pharmaceuticals' Second Quarter 2013 Financial Results Conference Call
Aug 06 Earnings Second Quarter 2013 Financial Results. Estimate: -0.27.
Jun 25 Misc AGM Event for Isis Pharmaceuticals, Inc.
May 07 Misc Q1 2013 Isis Pharmaceuticals Earnings Conference Call
May 07 Earnings Isis Reports Financial Results. Estimate: -0.12.
View All Performance Charts

ISIS Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Isis Pharmaceuticals is up 58.94% over the last year vs S&P 500 Total Return up 21.54%, Actelion up 67.22%, and Alnylam Pharmaceuticals up 124.1%.

Get Quote for

PDF Report for ISIS

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download ISIS Pro Report PDF

Portfolio Strategies Featuring ISIS

Did Isis Pharmaceuticals make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

ISIS Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: California
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Pharmaceutical Preparation Manufacturing
  • NAICS Code: 325412
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

Isis Pharmaceuticals, Inc. is engaged in the development and commercialization of drugs to treat various health conditions, including inflammatory, viral, metabolic and cardiovascular and dermatological diseases and cancer. The company through its primary technology, Antisense, creates inhibitors designed to hybridize with their RNA target and modulate the production of proteins associated with diseases. The company has strategic alliances and collaboration agreements primarily with GlaxoSmithKline; Genzyme Corporation; Archemix Corp.; Alnylam Pharmaceuticals, Inc.; Bristol-Myers Squibb; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; and Eli Lilly and Company. It was founded in January 1989 by Stanley T. Crooke and is headquartered in Carlsbad, California.

Recent Quotes

Symbol Price Chg Chg % Market Cap
ISIS 35.20 +0.00 +0.00% 4.130B
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.